Access to Cancer Drugs in Canada

Curr Oncol. 2022 Oct 12;29(10):7583-7586. doi: 10.3390/curroncol29100598.

Abstract

Lung cancer, because of the multiple subtypes now identifiable and because of the myriad of new and effective therapies, provides fertile ground to highlight issues related to oncology drug access in Canada [...].

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Canada
  • Humans
  • Lung Neoplasms* / drug therapy

Substances

  • Antineoplastic Agents

Grants and funding

This research received no external funding.